237 related articles for article (PubMed ID: 26911639)
1. Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies.
Sperling MR; French J; Jacobson MP; Pazdera L; Gough M; Cheng H; Grinnell T; Blum D;
Neurology; 2016 Mar; 86(12):1095-102. PubMed ID: 26911639
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America.
Sperling MR; Harvey J; Grinnell T; Cheng H; Blum D;
Epilepsia; 2015 Apr; 56(4):546-55. PubMed ID: 25689448
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.
Jacobson MP; Pazdera L; Bhatia P; Grinnell T; Cheng H; Blum D;
BMC Neurol; 2015 Mar; 15():46. PubMed ID: 25880756
[TBL] [Abstract][Full Text] [Related]
4. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine.
Pazdera L; Sperling MR; Harvey JH; Sam MC; Strom LA; Blum D; Grinnell T; Cheng H
Epilepsia; 2018 Mar; 59(3):704-714. PubMed ID: 29450890
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in patients treated with eslicarbazepine acetate monotherapy: Pooled analysis from two registered clinical trials.
Cramer JA; Rajagopalan K; Anastassopoulos KP; Blum D;
Epilepsy Behav; 2019 Mar; 92():31-35. PubMed ID: 30611005
[TBL] [Abstract][Full Text] [Related]
9. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P
CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894
[TBL] [Abstract][Full Text] [Related]
10. Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy.
Sunkaraneni S; Passarell JA; Ludwig EA; Fiedler-Kelly J; Pitner JK; Grinnell TA; Blum D
Clin Pharmacol; 2017; 9():65-72. PubMed ID: 28721105
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study.
Trinka E; Rocamora R; Chaves J; Moreira J; Ikedo F; Soares-da-Silva P;
Epilepsia; 2020 Oct; 61(10):2129-2141. PubMed ID: 32944934
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.
Gil-Nagel A; Elger C; Ben-Menachem E; Halász P; Lopes-Lima J; Gabbai AA; Nunes T; Falcão A; Almeida L; da-Silva PS
Epilepsia; 2013 Jan; 54(1):98-107. PubMed ID: 22882018
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics and Exposure-Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial-Onset Seizures.
Sunkaraneni S; Ludwig EA; Passarell JA; Blum D; Grinnell T; Fiedler-Kelly J
J Clin Pharmacol; 2018 Jul; 58(7):927-938. PubMed ID: 29528499
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.
Biton V; Rogin JB; Krauss G; Abou-Khalil B; Rocha JF; Moreira J; Gama H; Trinka E; Elger CE; Cheng H; Grinnell T; Blum D;
Epilepsy Behav; 2017 Jul; 72():127-134. PubMed ID: 28575761
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.
Toledano R; Jovel CE; Jiménez-Huete A; Bayarri PG; Campos D; Gomariz EL; Giráldez BG; García-Morales I; Falip M; Agredano PM; Palao S; Prior MJAA; Pascual MRQ; Navacerrada FJ; González FJL; Ojeda J; Sáez AA; Bermejo PE; Gil-Nagel A
Epilepsy Behav; 2017 Aug; 73():173-179. PubMed ID: 28641170
[TBL] [Abstract][Full Text] [Related]
17. MONOZEB: Long-term observational study of eslicarbazepine acetate monotherapy.
Villanueva V; Bermejo P; Montoya J; Massot-Tarrús A; Galiano ML; Toledo M; Rodriguez-Uranga JJ; Bertol V; Mauri JÁ; Poza JJ; Bonet M; Castro-Vilanova MD; Ruiz-Giménez J; López-González FJ; Rodríguez-Osorio X; Tortosa-Conesa D; Ojeda J; Giner P; Garcés M; Alvarez BM; Quiroga-Subirana P; Esteve P; Baiges JJ; Hampel K
Epilepsy Behav; 2019 Aug; 97():51-59. PubMed ID: 31181429
[TBL] [Abstract][Full Text] [Related]
18. Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies.
Arnold S; Badalamenti V; Diaz A; Gasalla T; McShea C; Whitesides J; Fakhoury T
Epilepsy Res; 2018 Mar; 141():73-82. PubMed ID: 29486396
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.
Trinka E; Ben-Menachem E; Kowacs PA; Elger C; Keller B; Löffler K; Rocha JF; Soares-da-Silva P
Epilepsia; 2018 Feb; 59(2):479-491. PubMed ID: 29369348
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.
Perucca E; Elger C; Halász P; Falcão A; Almeida L; Soares-da-Silva P
Epilepsy Res; 2011 Sep; 96(1-2):132-9. PubMed ID: 21680153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]